A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (PTS) with advanced or metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Maroun, Jean A. [1 ]
Jonker, Derek [1 ]
Goel, Rakesh [1 ]
Cripps, Christine [1 ]
Lister, Diane [1 ]
Chiritescu, Gabriela [1 ]
机构：
[1] Ottawa Hosp, Reg Canc Ctr, Ottawa, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [41] Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer
    Cartwright, Thomas
    Kuefler, Paul
    Cohn, Allen
    Hyman, William
    Berger, Maury
    Richards, Donald
    Vukelja, Svetislava
    Nugent, John E.
    Ruxer, Robert L., Jr.
    Boehm, Kristi A.
    Asmar, Lina
    CLINICAL COLORECTAL CANCER, 2008, 7 (06) : 390 - 397
  • [42] An open-label phase II study of intermittent oral capecitabine (X) as first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC)
    Zhongzhen, G
    Fengyi, F
    Xiaoqing, L
    Yajie, W
    Baoming, Y
    Qionghua, Z
    Lin, S
    Shiying, Y
    Huaqing, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 303S - 303S
  • [43] Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
    Cupini, S.
    Bursi, S.
    Masi, G.
    Loupakis, F.
    Barbara, C.
    Fornaro, L.
    Allegrini, G.
    Di Marsico, R.
    Andreuccetti, M.
    Falcone, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 251 - 251
  • [44] First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
    E van Meerten
    F A L M Eskens
    E C van Gameren
    L Doorn
    A van der Gaast
    British Journal of Cancer, 2007, 96 : 1348 - 1352
  • [45] IXOA regimen, irinotecan (I), capecitabine (X), oxaliplatin (O), and bevacizumab (A), as first-line therapy for advanced unresectable colorectal cancer (aCRC): Preliminary results.
    Maroun, Jean Alfred
    Jonker, Derek J.
    Cripps, M. Christine
    Goel, Rakesh
    Asmis, Timothy R.
    Goodwin, Rachel Anne
    Yarom, Nirit
    Marginean, Horia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [46] First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
    van Meerten, E.
    Eskens, F. A. L. M.
    van Gameren, E. C.
    Doorn, L.
    van der Gaast, A.
    BRITISH JOURNAL OF CANCER, 2007, 96 (09) : 1348 - 1352
  • [47] Oxaliplatin and Capecitabine (CAPOX) in Non Selected Patients With Metastatic Colorectal Cancer (MCRC) After First-line Irinotecan Based Regimen
    Fonseca, P. J.
    Solis, P.
    Vieitez, J. M.
    Izquierdo, M.
    Pardo, P.
    Gutierrez, E.
    Perez, Q.
    Alvarez, C.
    Frunza, M.
    Uriol, E.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S422 - S423
  • [48] Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
    Schmiegel, W.
    Reinacher-Schick, A.
    Arnold, D.
    Kubicka, S.
    Freier, W.
    Dietrich, G.
    Geissler, M.
    Hegewisch-Becker, S.
    Tannapfel, A.
    Pohl, M.
    Hinke, A.
    Schmoll, H. J.
    Graeven, U.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1580 - 1587
  • [49] Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
    Yamada, Y.
    Tahara, M.
    Miya, T.
    Satoh, T.
    Shirao, K.
    Shimada, Y.
    Ohtsu, A.
    Sasaki, Y.
    Tanigawara, Y.
    BRITISH JOURNAL OF CANCER, 2008, 98 (06) : 1034 - 1038
  • [50] Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
    Y Yamada
    M Tahara
    T Miya
    T Satoh
    K Shirao
    Y Shimada
    A Ohtsu
    Y Sasaki
    Y Tanigawara
    British Journal of Cancer, 2008, 98 : 1034 - 1038
12345